Arnold & Porter

SIGA Names Larry Miller General Counsel

Retrieved on: 
Monday, March 25, 2024
SIGA Technologies, Growth, Patient, Sale, Dartmouth College, General Mills, Infection, Pfizer, Columbia Law School, Intellectual property, Weil, Gotshal & Manges, Arnold & Porter

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today.

Key Points: 
  • NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today.
  • “Larry will be instrumental in helping us expand our reach on a global scale and maximize the benefits we bring to patients, customers, and shareholders.”
    Previously, Mr. Miller served as general counsel and secretary at Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal disorders.
  • He also served as general counsel and secretary at Blue Buffalo Company, advising the company through its $8 billion sale to General Mills.
  • “I’m excited to join the SIGA team and help support its important mission of providing solutions for unmet needs in health security and infectious diseases,” said Mr. Miller.

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Retrieved on: 
Monday, March 18, 2024
Civil service commission, Neuroblastoma, Ototoxicity, Partnership, Central nervous system, ANZ, Risk, FENC, Patient, Hepatoblastoma, Neoplasm, Cancer, MHRA, TSX, Hearing loss, European, Cisplatin, Safety, European Commission, Liver, Arnold & Porter, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C. and UXBRIDGE, United Kingdom, March 17, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to

Key Points: 
  • Norgine will be responsible for all commercialization activities in the licensed territories and will hold all marketing authorizations in the licensed territories.
  • It is estimated that more than 5,000 pediatric patients annually are eligible for platinum-based chemotherapy in Europe.
  • PEDMARQSI was granted EU marketing authorization by the European Commission in June 2023, and received UK approval from the MHRA in October 2023.
  • The studies compared PEDMARQSI plus cisplatin-based regimens to cisplatin-based regimens alone for the reduction of cisplatin-induced hearing loss in pediatric patients.

Seyfarth Expands Capital Markets Capabilities in New York With Addition of Alex Gendzier

Retrieved on: 
Tuesday, April 2, 2024
Consulting, Professional Services, Legal, Haverford College, Veteran, Windward School, Team leader, Bankers Trust, PIPES, Trustee, Knowledge, Insolvency, Phi Beta Kappa, Order of the Coif, Dwight School, Investment, Coif, University School, Arnold & Porter

Seyfarth Shaw LLP announced today the strategic enhancement of the firm’s corporate department with the arrival in New York of partner Alex Gendzier , a leading capital markets and restructuring attorney.

Key Points: 
  • Seyfarth Shaw LLP announced today the strategic enhancement of the firm’s corporate department with the arrival in New York of partner Alex Gendzier , a leading capital markets and restructuring attorney.
  • “He is a known quantity in corporate debt and equity capital markets space and he has a stellar reputation as one of the leading securities practitioners in New York.
  • His addition further strengthens our capital markets service offering as well as our new Transactional Restructuring & Insolvency team.”
    Gendzier represents companies, investors, alternative asset managers, private equity firms and family offices across the spectrum of capital markets transactions and investments, whether healthy or distressed.
  • “Alex’s expertise in all major types of capital markets transactions, makes him an ideal fit for Seyfarth’s corporate department and our New York office,” said Steven Meier , Seyfarth’s corporate department chair.

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Retrieved on: 
Monday, March 18, 2024
Civil service commission, Neuroblastoma, Ototoxicity, Partnership, Central nervous system, ANZ, Risk, FENC, Patient, Hepatoblastoma, Neoplasm, Cancer, MHRA, TSX, Hearing loss, European, Cisplatin, Safety, European Commission, Liver, Arnold & Porter, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C. and UXBRIDGE, England, March 18, 2024 /PRNewswire/ -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to

Key Points: 
  • Norgine will be responsible for all commercialization activities in the licensed territories and will hold all marketing authorizations in the licensed territories.
  • It is estimated that more than 5,000 pediatric patients annually are eligible for platinum-based chemotherapy in Europe.
  • The studies compared PEDMARQSI plus cisplatin-based regimens to cisplatin-based regimens alone for the reduction of cisplatin-induced hearing loss in pediatric patients.
  • Moelis & Company LLC acted as financial advisor, and LaBarge Weinstein LLP acted as legal advisor to Fennec.

Biocom California Appoints New Members to its Board of Governors

Retrieved on: 
Wednesday, February 7, 2024
Health, Genetics, Practice Management, General Health, Pharmaceutical, Biotechnology, San Francisco Bay Area, Growth, Alexandria Real Estate Equities, Heller, Duke University, Investment, Heller Ehrman, Region, Poverty, Economics, Pennsylvania State University, Arnold & Porter, GE Capital, University, Gilead Sciences, LLP, Quality, University of San Diego, Management

Biocom California, the association representing the California life science industry, today announced that it appointed Jeffrey Hessekiel, executive vice president and general counsel at Exelixis, and Michael Boss, senior vice president at Alexandria Real Estate Equities, to its board of governors.

Key Points: 
  • Biocom California, the association representing the California life science industry, today announced that it appointed Jeffrey Hessekiel, executive vice president and general counsel at Exelixis, and Michael Boss, senior vice president at Alexandria Real Estate Equities, to its board of governors.
  • Hessekiel and Mr. Boss are valuable additions to our board of governors, which consists of prominent life science leaders with deep industry knowledge representing regions across the state,” said Joe Panetta, president and CEO of Biocom California.
  • Before Exelixis, Mr. Hessekiel was senior counsel at the law firm Arnold & Porter, and previously worked at Gilead Sciences.
  • His region covered Southern California, Phoenix, and Las Vegas, as well as all product types including life science, industrial, office, multi-family, and retail.

Murray R. Garnick, Executive Vice President & General Counsel, Announces Decision to Retire

Retrieved on: 
Thursday, February 1, 2024
Retail, Professional Services, Tobacco, Legal, Specialty, ABI, Horizon, Family, Senior, General counsel, ALCS, NJOY, PM, Heated tobacco product, FDA, Marketing, Investment, AB InBev, Food, Helix, MST, Smoker, Associate, Health, Arnold & Porter, Private practice

(NYSE: MO) Murray R. Garnick, Executive Vice President & General Counsel of Altria Group, Inc. (Altria), has notified the company of his decision to retire effective April 1, 2024.

Key Points: 
  • (NYSE: MO) Murray R. Garnick, Executive Vice President & General Counsel of Altria Group, Inc. (Altria), has notified the company of his decision to retire effective April 1, 2024.
  • “In addition to Murray’s significant individual contributions, his passion for developing world-class legal and regulatory talent has contributed tremendously to Altria’s success.
  • I am grateful for his many contributions, and I wish him the best in retirement.”
    Robert (Bob) A. McCarter will become Altria’s Executive Vice President & General Counsel effective April 1, 2024.
  • Currently Bob serves as Senior Vice President & Associate General Counsel, ALCS, where he supervises the management of tobacco, health and other litigation.

Jennifer Patterson joins Haug Partners LLP’s Antitrust group

Retrieved on: 
Wednesday, January 3, 2024
Legal, Professional Services, Arnold & Porter, Accounting, Intellectual property, Partner, State, Justice, FDA, Fortune 500, Vanderbilt University, LLP, Publishing, Food, Georgetown University Law Center, IP, State attorney general, Pesticide, Transport, Biometrics, Kaye Scholer

Haug Partners LLP is excited to welcome Jennifer Patterson as a partner in its New York office.

Key Points: 
  • Haug Partners LLP is excited to welcome Jennifer Patterson as a partner in its New York office.
  • Ed Haug, Chairman of the Firm, had this to say about Jennifer’s addition: “As we start 2024, we are very excited to welcome Jennifer Patterson as partner in our antitrust practice.
  • We welcome Jennifer to our already robust and very successful antitrust practice.”
    In joining the Firm, Ms. Patterson commented: “I was drawn to Haug Partners because of its sophisticated antitrust litigation practice and its integrated IP platform.
  • Haug Partners LLP is a national law firm that provides integrated, multidisciplinary legal services in the areas of Intellectual Property, FDA law, and antitrust and commercial transactions.

Pfizer Completes Acquisition of Seagen

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NYSE, Research, Policy, Acquisition, PFE, Spacecraft, LLP, Avelumab, Investment, ADC, Brentuximab vedotin, Antibody-drug conjugate, Protein engineering, Sullivan & Cromwell, Science, Centerview Partners, Oliver Cromwell, AACR, Cancer, Death, Financial toxicity, Communication, Federal Trade Commission, Growth, Guggenheim Partners, Inc., Arnold & Porter, Conjugation, Education, Pharmaceutical industry, Fine chemical, Pfizer, Seagen

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.
  • Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
  • With the addition of Seagen, Pfizer’s Oncology pipeline has doubled in size with 60 programs spanning multiple modalities, including ADCs, small molecules, bispecifics and other immunotherapies.
  • “This is a great day for Pfizer, and, more importantly, for people living with cancer, as we bring together the game-changing science and top talent of Seagen and Pfizer to form a leading Oncology organization,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.

Legends Announces Acquisition of ASM Global

Retrieved on: 
Tuesday, November 7, 2023
Entertainment, Sports, Other Entertainment, General Entertainment, Other Sports, Events, Concerts, General Sports, Dallas Cowboys, Goldman Sachs, Ryder Cup, NFL, Real Madrid CF, SoFi Stadium, University of Notre Dame, Coca-Cola Arena, PGA, Subway Series, Dallas, Acquisition, State Farm Stadium, Multimedia, Professional Golfers' Association of America, Arnold, NASCAR, MLB, Growth, BofA Securities, AEG, Avicii Arena, Partnership, Onex, Wembley Arena, Latham & Watkins, University, Ropes & Gray, Jefferies, Anschutz Entertainment Group, ASM, FC Barcelona, Arnold & Porter, New York Yankees, Legend

Legends and ASM Global today announced the signing of a definitive agreement under which Legends will acquire ASM Global to create a premium live events company dedicated to providing outstanding experiences for fans around the world.

Key Points: 
  • Legends and ASM Global today announced the signing of a definitive agreement under which Legends will acquire ASM Global to create a premium live events company dedicated to providing outstanding experiences for fans around the world.
  • “Legends and ASM Global are both deeply client-centric and fan-focused and together we will deliver maximum value for our global client roster with even greater support and service options,” said Shervin Mirhashemi, CEO of Legends.
  • ASM Global manages a portfolio of live event entertainment venues worldwide and provides best-in-class venue operation and content and event booking.
  • As part of the transaction, current ASM Global equity holders Onex and AEG will sell their ownership interests.

Leading Commercial Litigation Partner Susan Shin Joins Hunton Andrews Kurth in New York

Retrieved on: 
Monday, September 11, 2023
LLP, Health, Arnold & Porter, Daniel Inouye, Chambers, Policy, Shin, The American Lawyer, RMBS, Multidistrict litigation, RICO, Lawyer, Publication, Rutgers University, MDL, Weil, Gotshal & Manges, District court, Chambers and Partners, Supreme court, The National Law Journal, Arnold, American Bar Association, Hague Convention, Columbia Law School, Tobacco, Real estate, Insurance

New York, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Susan L. Shin , a highly regarded and nationally recognized complex commercial litigation and trial attorney, has joined Hunton Andrews Kurth LLP as a partner in New York.

Key Points: 
  • New York, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Susan L. Shin , a highly regarded and nationally recognized complex commercial litigation and trial attorney, has joined Hunton Andrews Kurth LLP as a partner in New York.
  • Shin joins Hunton Andrews Kurth from Weil, Gotshal & Manges, LLP, where she was a partner in the complex litigation practice.
  • Since our founding in 1901, Hunton Andrews Kurth has been a business-focused firm, an approach that we bring to today’s litigation climate.
  • With lawyers in the United States, Asia, Europe and the Middle East, Hunton Andrews Kurth LLP serves clients across a broad range of complex transactional, litigation and regulatory matters.